News Articles
Browse our entire archive of news articles, spotlight interviews, and other editorial pieces in one place.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters
Tag
Molecular Science Corp. Receives GMP Licence From Health Canada
Molecular Science Corp.
Champignon Ketamine Treatment to be Dispensed by Major Canadian Pharmacy Chain; Closes AltMed
Braxia Scientific Corp.
Champignon Brands Selected as Headline Partner for Psych: The Psychedelics Symposium at Prohibition Partners Live
Braxia Scientific Corp.
Compass Pathways Raises $80 Million to Prepare its Psilocybin Therapy for Phase 3 Development
Compass Pathways
COMPASS Pathways Concludes Successful $80M Series B Investment Round
ATAI Life Sciences
Compass Pathways
Hollister Biosciences Enters Into Definitive Agreement to Acquire AlphaMind Brands Inc.
No items found.
Champignon commences U.S. trading on the OTCQB Venture Market under ticker symbol $SHRMF
Braxia Scientific Corp.
Empower Clinics Continues To Advance Development Of Psilocybin And Psychedelics Division To Address Significant Mental Health Issues
No items found.
Champignon Brands secures stable psilocybin supply under DEA Schedule I license for TBI/PTSD studies at the University of Miami
Braxia Scientific Corp.
Field Trip Psychedelics Inc. Announces Launch of Virtual Psychedelic Therapy and COVID-Coping Therapy
Field Trip Health
MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips
Mind Medicine (MindMed)
Field Trip Psychedelics Inc. Announces Creation of Field Trip Discovery, the Company's Drug Development Division
Field Trip Health
Champignon Brands Acquires AltMed
Braxia Scientific Corp.
Srinivas Rao, MD, Ph.D. | Chief Scientific Officer, Atai Life Sciences
ATAI Life Sciences
JR Rahn | MindMed
Mind Medicine (MindMed)
Roger McIntyre, M.D. | CEO, Champignon Brands
Braxia Scientific Corp.
Champignon Brands
Braxia Scientific Corp.
Ronan Levy | Field Trip Health
Field Trip Health
Get the Headlines & Market Updates
Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.